Developer docs
API playgroundTry for free, no card

Search company profiles

Spatial Transcriptomics

Full company profile

uuid002cht7

Namestring
Spatial Transcriptomics
Legal namestring
10x Genomics, Inc.
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Spatial Transcriptomics operates as a brand and trademark of 10x Genomics, Inc., a life science tools company headquartered in Pleasanton, California. The company provides spatial transcriptomics and single cell analysis platforms that enable researchers to perform RNA sequencing with preserved two-dimensional tissue context, addressing the loss of spatial information inherent to traditional bulk and dissociated single cell methods. Core technology comprises four platforms: Visium Spatial (whole-transcriptome spatial discovery using probe-based or 3' poly(A) chemistries on a 2 μm x 2 μm barcoded slide architecture), Xenium In Situ (high-resolution single cell spatial imaging with sub-30 nm XY transcript localization precision and up to 5,000-gene customizable panels), Atera In Situ (scalable whole-transcriptome spatial profiling at subcellular resolution with up to 800 samples per year), and Chromium Single Cell (multiomic single cell processing at scale). Supporting software includes Cell Ranger, Space Ranger, and Loupe, with 10x Genomics Cloud providing instrument connectivity and data analysis. The patented stack is sold for research use only across human, mouse, rat, and other species using FFPE, fresh frozen, and fixed frozen samples.

The company monetizes through a razor-and-blade model: instrument sales (Visium CytAssist, Xenium Analyzer, Atera Instrument, Chromium instruments), high-margin recurring consumables (probe panels, microfluidic cartridges, reagent kits), subscription-style software licenses (Loupe, Cell Ranger, Space Ranger), and professional services such as Premium Automation Enablement. Distribution combines direct enterprise field sales with a global authorized distributor network; pricing is quote-based with multi-year contracts, and products are explicitly labeled for research use only. End customers are segmented across Pharma & Biotech (drug development, biomarker discovery, clinical trial optimization), Oncology Research (tumor microenvironment, immune cell mapping), Immunology (immune cell characterization and immunotherapy development), and AI & Computational Biology (training AI cell models and virtual cell development), supported by a scientific community of over 10,000 publications citing the technology. Founders Jonas Frisén and Patrik Ståhl are credited as originators of the spatial barcoding approach underlying the portfolio.

Note on data scope: the firmographic record (1-10 employees, Stockholm, founded 2016) describes the original Swedish Spatial Transcriptomics entity, while the operational data reflects 10x Genomics, Inc., the acquirer and current owner of the Spatial Transcriptomics trademark. This analysis treats the company as the operating entity represented by the operational data.

Short descriptiontext

Spatial Transcriptomics, a brand of 10x Genomics, Inc., provides spatial transcriptomics and single cell analysis platforms (Visium, Xenium, Atera, Chromium) that enable researchers to perform 2D RNA sequencing across FFPE and fresh frozen tissue, serving pharma, biotech, oncology, immunology, and AI/computational biology customers worldwide via enterprise field sales and a global distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersStockholm, Sweden
HQ citystring
Stockholm
HQ countrystring
Sweden
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
spatial transcriptomics, single cell analysis, in situ imaging, RNA sequencing platforms, multiomics genomics
Industry4 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Spatial Transcriptomics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument Sales
TypeHardware Sales
Description

Sale of 10x branded instruments including Visium CytAssist, Xenium Analyzer, Atera Instrument, and Chromium instruments along with associated accessories.

10xgenomics.com
2Consumables
TypeHardware Sales
Description

Sale of 10x reagents, microfluidic cartridges, reagent kits, and labware intended for single use with 10x Instruments. Products include probe-based and 3' poly(A) capture-based assays.

10xgenomics.com
3Software Licenses
TypeSubscription Recurring
Description

Licensing of 10x software including Loupe Software, Cell Ranger, Space Ranger, and other data analysis software for genomic assembly, phasing, cell analysis and visualization.

10xgenomics.com
4Premium Automation Enablement Services
TypeProfessional Services
Description

Automation enablement services to enable and validate third party automation platforms applied to 10x workflows, including consultation and execution support.

10xgenomics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure
Pricing details1 tier
1Custom Enterprise Pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing varies by product configuration, volume, and customer requirements. Contact sales specialist for quote.

10xgenomics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Visium
Description

Spatial assays for whole transcriptome spatial discovery at single cell scale

10xgenomics.com
+4 more records
Core offering1 text field

Spatial Transcriptomics provides spatial transcriptomics technology that allows researchers to perform RNA sequencing in 2D. The offering spans proprietary platforms including Visium HD Spatial Assays (2 μm x 2 μm barcoded squares), Xenium Analyzer (single cell spatial imaging with nanometer-level localization precision), Atera In Situ (scalable whole transcriptome spatial at subcellular resolution with up to 800 samples per year), and Chromium Single Cell, supported by bioinformatics software (Loupe, Cell Ranger, Space Ranger) and consumables for FFPE, fresh frozen, and fixed frozen tissue samples.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 800 1 cm² whole transcriptome samples per year with Atera platform
+2 more records
Product overview1 text field

10x Genomics offers a comprehensive spatial transcriptomics portfolio under the Visium, Xenium, and Atera platforms, providing whole transcriptome spatial discovery at single cell scale. The Visium Spatial platform uses probe-based (HD WT Panel) or 3' capture-based (HD 3') chemistries with CytAssist instrumentation for FFPE and fresh frozen tissue. The Xenium In Situ platform delivers high-resolution spatial imaging with the Xenium Analyzer (up to 5,000 genes, 472 mm² per run) plus customizable panels and protein subpanels for multiomic analysis. The Atera In Situ platform provides scalable throughput (up to 800 samples/year) at whole-transcriptome scale. Supporting these core spatial platforms, Chromium Single Cell enables single cell multiomics, 10x Genomics Cloud provides instrument connectivity and data analysis, and Premium Automation Enablement services support integration with third-party automation systems.

Product and service7 records
1Visium Spatial Assays
CategorySpatial Transcriptomics Assay
Description

Whole transcriptome spatial discovery platform at single cell scale using either probe-based (HD WT Panel) or 3' poly(A) capture-based (HD 3') chemistry. Compatible with FFPE, fresh frozen, and fixed frozen tissue samples from human, mouse, and rat.

2Visium CytAssist
CategoryInstrument
Description

Instrument used with Visium Spatial assays for tissue processing and spatial gene expression analysis, simplifying workflow and expanding sample access for FFPE and fresh frozen tissue.

3Xenium Analyzer
CategoryInstrument
Description

State-of-the-art single cell spatial imaging platform that integrates transcript detection workflow, high-resolution imaging, decoding, and onboard data analysis. Analyzes 472 mm² of tissue per run, targeting up to 480 genes in under 3 days or up to 5,000 genes in under 6 days.

4Xenium Panels
CategoryReagent Panel
Description

Ready-to-use and customizable RNA panels using Xenium Prime chemistry, supporting up to 5,000 genes with options for 9 tissue-specific and 2 comprehensive human/mouse panels, plus multiomic analysis capability including protein subpanels. Compatible with FFPE and fresh frozen tissue.

5Atera In Situ Platform
CategorySpatial Transcriptomics Platform
Description

Scalable whole transcriptome spatial platform at subcellular resolution. Delivers up to 800 samples per year at whole-transcriptome scale with single cell sensitivity and unmatched throughput.

6Chromium Single Cell
CategorySingle Cell Analysis Platform
Description

Single cell multiomics platform for analysis of thousands of samples and billions of cells, including FFPE samples. Powers research breakthroughs across cancer research, immunology, neuroscience, and developmental biology.

7Premium Automation Enablement (PAE)
CategoryProfessional Services
Description

Service package designed to help automate assay workflows with third-party automation platforms. Includes strategic coordination sessions, automation documentation, remote support, on-site FAS support, and final data review commentary.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Single cell multiomics platform focused on genomics and proteomics at single cell resolution, with overlapping applications in cancer research and clonal evolution studies where Chromium is also used.

TypeDirect peer
Description

Offers mass cytometry (Helios/Hyperion) and imaging mass cytometry platforms for single cell and spatial tissue analysis, overlapping with Chromium single cell multiomics in immunology and oncology customer segments.

TypeDirect peer
Description

Commercializes MERFISH-based spatial transcriptomics technology, a direct in situ imaging competitor to Xenium Analyzer, with overlapping customer base in academic and pharma translational research.

TypeDirect peer
Description

Operates the GeoMx Digital Spatial Profiler and CosMx SMI platform for spatial transcriptomics, directly competing with Visium, Xenium, and Atera across both sequencing-based and imaging-based spatial workflows. Acquired by Bruker in 2024.

TypeBroad incumbent
Description

Provides ddPCR, Droplet Digital PCR, and life science research instruments, with broader reach in genomics workflows that partially overlap with the company's molecular biology instrumentation footprint.

TypeBroad incumbent
Description

Dominant sequencing platform provider whose NGS instruments underpin downstream Visium and Chromium workflows. A strategic upstream/downstream incumbent rather than a direct spatial transcriptomics competitor, but with capacity to enter the space.

TypeEmerging player
Description

Develops the G4 sequencing platform with applications in spatial and single cell genomics; an emerging NGS platform competitor that could intersect with Visium library preparation and downstream sequencing workflows.

TypeDirect peer
Description

Offers the PhenoCycler and PhenoImager spatial biology platforms for multiplex immunofluorescence and spatial phenotyping, overlapping with Visium/Xenium in tumor microenvironment and immunology research segments.

TypeBroad incumbent
Description

Acquired NanoString and offers mass-spec-based and spatial biology solutions through its Bruker Spatial Biology division, providing a broad life sciences tools portfolio that increasingly overlaps with the company's spatial transcriptomics offerings.

TypeOthers
Description

The parent/operating entity that owns the Spatial Transcriptomics brand and operates the Visium, Xenium, Atera, and Chromium platforms. Listed for context given the conflation evident in the company data; not a true competitive peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spatial Transcriptomics

Spatial Transcriptomicsspatialtranscriptomics.com

Spatial Transcriptomics, a brand of 10x Genomics, Inc., provides spatial transcriptomics and single cell analysis platforms (Visium, Xenium, Atera, Chromium) that enable researchers to perform 2D RNA sequencing across FFPE and fresh frozen tissue, serving pharma, biotech, oncology, immunology, and AI/computational biology customers worldwide via enterprise field sales and a global distributor network.

What Spatial Transcriptomics does

Spatial Transcriptomics operates as a brand and trademark of 10x Genomics, Inc., a life science tools company headquartered in Pleasanton, California. The company provides spatial transcriptomics and single cell analysis platforms that enable researchers to perform RNA sequencing with preserved two-dimensional tissue context, addressing the loss of spatial information inherent to traditional bulk and dissociated single cell methods. Core technology comprises four platforms: Visium Spatial (whole-transcriptome spatial discovery using probe-based or 3' poly(A) chemistries on a 2 μm x 2 μm barcoded slide architecture), Xenium In Situ (high-resolution single cell spatial imaging with sub-30 nm XY transcript localization precision and up to 5,000-gene customizable panels), Atera In Situ (scalable whole-transcriptome spatial profiling at subcellular resolution with up to 800 samples per year), and Chromium Single Cell (multiomic single cell processing at scale). Supporting software includes Cell Ranger, Space Ranger, and Loupe, with 10x Genomics Cloud providing instrument connectivity and data analysis. The patented stack is sold for research use only across human, mouse, rat, and other species using FFPE, fresh frozen, and fixed frozen samples.

The company monetizes through a razor-and-blade model: instrument sales (Visium CytAssist, Xenium Analyzer, Atera Instrument, Chromium instruments), high-margin recurring consumables (probe panels, microfluidic cartridges, reagent kits), subscription-style software licenses (Loupe, Cell Ranger, Space Ranger), and professional services such as Premium Automation Enablement. Distribution combines direct enterprise field sales with a global authorized distributor network; pricing is quote-based with multi-year contracts, and products are explicitly labeled for research use only. End customers are segmented across Pharma & Biotech (drug development, biomarker discovery, clinical trial optimization), Oncology Research (tumor microenvironment, immune cell mapping), Immunology (immune cell characterization and immunotherapy development), and AI & Computational Biology (training AI cell models and virtual cell development), supported by a scientific community of over 10,000 publications citing the technology. Founders Jonas Frisén and Patrik Ståhl are credited as originators of the spatial barcoding approach underlying the portfolio.

Note on data scope: the firmographic record (1-10 employees, Stockholm, founded 2016) describes the original Swedish Spatial Transcriptomics entity, while the operational data reflects 10x Genomics, Inc., the acquirer and current owner of the Spatial Transcriptomics trademark. This analysis treats the company as the operating entity represented by the operational data.

Spatial Transcriptomics firmographics

Firmographics
Name
Spatial Transcriptomics
Legal name
10x Genomics, Inc.
Website
https://spatialtranscriptomics.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Spatial Transcriptomics, a brand of 10x Genomics, Inc., provides spatial transcriptomics and single cell analysis platforms (Visium, Xenium, Atera, Chromium) that enable researchers to perform 2D RNA sequencing across FFPE and fresh frozen tissue, serving pharma, biotech, oncology, immunology, and AI/computational biology customers worldwide via enterprise field sales and a global distributor network.
Ownership category
akta.pro rank

Spatial Transcriptomics industry classification

Industry
Product category
Spatial Transcriptomics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAGANAE
Transcriptomics & Gene Expression Profiling Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)

Keywords

  • Spatial transcriptomics
  • Single cell analysis
  • In situ imaging
  • RNA sequencing platforms
  • Multiomics genomics

Where Spatial Transcriptomics is headquartered

Location

Headquarters

HQ city
Stockholm
HQ country
Sweden
HQ region
Europe

Offices1 record

Markets served

Spatial Transcriptomics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Supply Chain, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Instrument Sales: Sale of 10x branded instruments including Visium CytAssist, Xenium Analyzer, Atera Instrument, and Chromium instruments along with associated accessories.
  2. Consumables: Sale of 10x reagents, microfluidic cartridges, reagent kits, and labware intended for single use with 10x Instruments. Products include probe-based and 3' poly(A) capture-based assays.
  3. Software Licenses: Licensing of 10x software including Loupe Software, Cell Ranger, Space Ranger, and other data analysis software for genomic assembly, phasing, cell analysis and visualization.
  4. Premium Automation Enablement Services: Automation enablement services to enable and validate third party automation platforms applied to 10x workflows, including consultation and execution support.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom Enterprise Pricing

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Spatial Transcriptomics product offering

Product offering

Core offering

Spatial Transcriptomics provides spatial transcriptomics technology that allows researchers to perform RNA sequencing in 2D. The offering spans proprietary platforms including Visium HD Spatial Assays (2 μm x 2 μm barcoded squares), Xenium Analyzer (single cell spatial imaging with nanometer-level localization precision), Atera In Situ (scalable whole transcriptome spatial at subcellular resolution with up to 800 samples per year), and Chromium Single Cell, supported by bioinformatics software (Loupe, Cell Ranger, Space Ranger) and consumables for FFPE, fresh frozen, and fixed frozen tissue samples.

Product overview

10x Genomics offers a comprehensive spatial transcriptomics portfolio under the Visium, Xenium, and Atera platforms, providing whole transcriptome spatial discovery at single cell scale. The Visium Spatial platform uses probe-based (HD WT Panel) or 3' capture-based (HD 3') chemistries with CytAssist instrumentation for FFPE and fresh frozen tissue. The Xenium In Situ platform delivers high-resolution spatial imaging with the Xenium Analyzer (up to 5,000 genes, 472 mm² per run) plus customizable panels and protein subpanels for multiomic analysis. The Atera In Situ platform provides scalable throughput (up to 800 samples/year) at whole-transcriptome scale. Supporting these core spatial platforms, Chromium Single Cell enables single cell multiomics, 10x Genomics Cloud provides instrument connectivity and data analysis, and Premium Automation Enablement services support integration with third-party automation systems.

Differentiator

Problem solved

Functional benefit

Brands

  • Visium: Spatial assays for whole transcriptome spatial discovery at single cell scale
  • Xenium
  • Atera
  • Chromium
  • Premium Automation Enablement (PAE)

Products and services

  • Visium Spatial Assays Whole transcriptome spatial discovery platform at single cell scale using either probe-based (HD WT Panel) or 3' poly(A) capture-based (HD 3') chemistry. Compatible with FFPE, fresh frozen, and fixed frozen tissue samples from human, mouse, and rat.
  • Visium CytAssist Instrument used with Visium Spatial assays for tissue processing and spatial gene expression analysis, simplifying workflow and expanding sample access for FFPE and fresh frozen tissue.
  • Xenium Analyzer State-of-the-art single cell spatial imaging platform that integrates transcript detection workflow, high-resolution imaging, decoding, and onboard data analysis. Analyzes 472 mm² of tissue per run, targeting up to 480 genes in under 3 days or up to 5,000 genes in under 6 days.
  • Xenium Panels Ready-to-use and customizable RNA panels using Xenium Prime chemistry, supporting up to 5,000 genes with options for 9 tissue-specific and 2 comprehensive human/mouse panels, plus multiomic analysis capability including protein subpanels. Compatible with FFPE and fresh frozen tissue.
  • Atera In Situ Platform Scalable whole transcriptome spatial platform at subcellular resolution. Delivers up to 800 samples per year at whole-transcriptome scale with single cell sensitivity and unmatched throughput.
  • Chromium Single Cell Single cell multiomics platform for analysis of thousands of samples and billions of cells, including FFPE samples. Powers research breakthroughs across cancer research, immunology, neuroscience, and developmental biology.
  • Premium Automation Enablement (PAE) Service package designed to help automate assay workflows with third-party automation platforms. Includes strategic coordination sessions, automation documentation, remote support, on-site FAS support, and final data review commentary.

Quantifiable outcome

  • Up to 800 1 cm² whole transcriptome samples per year with Atera platform
  • +2 more outcomes

Companies that use Spatial Transcriptomics

Customer profile

Segments4 records

Ideal customer profiles4 records

Spatial Transcriptomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability5 records

Feature5 records

Spatial Transcriptomics partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves6 records

Expansion highlights6 records

Spatial Transcriptomics competitors and assessment

Company assessment

Emerging players

  • Mission Bio: Single cell multiomics platform focused on genomics and proteomics at single cell resolution, with overlapping applications in cancer research and clonal evolution studies where Chromium is also used.
  • Singular Genomics: Develops the G4 sequencing platform with applications in spatial and single cell genomics; an emerging NGS platform competitor that could intersect with Visium library preparation and downstream sequencing workflows.

Direct peers

  • Standard BioTools (formerly Fluidigm): Offers mass cytometry (Helios/Hyperion) and imaging mass cytometry platforms for single cell and spatial tissue analysis, overlapping with Chromium single cell multiomics in immunology and oncology customer segments.
  • Vizgen: Commercializes MERFISH-based spatial transcriptomics technology, a direct in situ imaging competitor to Xenium Analyzer, with overlapping customer base in academic and pharma translational research.
  • NanoString Technologies (Bruker Spatial Biology): Operates the GeoMx Digital Spatial Profiler and CosMx SMI platform for spatial transcriptomics, directly competing with Visium, Xenium, and Atera across both sequencing-based and imaging-based spatial workflows. Acquired by Bruker in 2024.
  • Akoya Biosciences: Offers the PhenoCycler and PhenoImager spatial biology platforms for multiplex immunofluorescence and spatial phenotyping, overlapping with Visium/Xenium in tumor microenvironment and immunology research segments.

Broad incumbents

  • Bio-Rad Laboratories: Provides ddPCR, Droplet Digital PCR, and life science research instruments, with broader reach in genomics workflows that partially overlap with the company's molecular biology instrumentation footprint.
  • Illumina: Dominant sequencing platform provider whose NGS instruments underpin downstream Visium and Chromium workflows. A strategic upstream/downstream incumbent rather than a direct spatial transcriptomics competitor, but with capacity to enter the space.
  • Bruker Corporation: Acquired NanoString and offers mass-spec-based and spatial biology solutions through its Bruker Spatial Biology division, providing a broad life sciences tools portfolio that increasingly overlaps with the company's spatial transcriptomics offerings.

Others

  • 10x Genomics: The parent/operating entity that owns the Spatial Transcriptomics brand and operates the Visium, Xenium, Atera, and Chromium platforms. Listed for context given the conflation evident in the company data; not a true competitive peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Spatial Transcriptomics social profiles

Digital presence

Spatial Transcriptomics compliance and trust

Trust signal

Compliance3 records

Spatial Transcriptomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spatial Transcriptomics leadership team

Management profile

Number of profiles

Profiles2 records

Spatial Transcriptomics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spatial Transcriptomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spatial Transcriptomics

What does Spatial Transcriptomics do?

Spatial Transcriptomics provides spatial transcriptomics technology that allows researchers to perform RNA sequencing in 2D. The offering spans proprietary platforms including Visium HD Spatial Assays (2 μm x 2 μm barcoded squares), Xenium Analyzer (single cell spatial imaging with nanometer-level localization precision), Atera In Situ (scalable whole transcriptome spatial at subcellular resolution with up to 800 samples per year), and Chromium Single Cell, supported by bioinformatics software (Loupe, Cell Ranger, Space Ranger) and consumables for FFPE, fresh frozen, and fixed frozen tissue samples.

Is Spatial Transcriptomics a public or private company?

Spatial Transcriptomics is a private company. It is classified as unknown and is currently operating.

When was Spatial Transcriptomics founded?

Spatial Transcriptomics was founded in 2016. It employs 1 to 10 people.

Where is Spatial Transcriptomics based?

Spatial Transcriptomics is headquartered in Stockholm, Sweden, in the Europe region.

How does Spatial Transcriptomics make money?

Four revenue lines are on record. Instrument Sales are the primary driver. The others are consumables, software Licenses and premium Automation Enablement Services.

Who are Spatial Transcriptomics's main competitors?

Emerging players on record are Mission Bio and Singular Genomics. Direct peers are Standard BioTools (formerly Fluidigm), Vizgen, NanoString Technologies (Bruker Spatial Biology) and Akoya Biosciences. Broad incumbents are Bio-Rad Laboratories, Illumina and Bruker Corporation. 10x Genomics is listed as an others.

Does Spatial Transcriptomics have an API?

No public API is recorded for Spatial Transcriptomics.

What industry is Spatial Transcriptomics in?

Spatial Transcriptomics's product category is Spatial Transcriptomics. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAGANAE, Transcriptomics & Gene Expression Profiling Services. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NatureMethod of the Year: spatially resolved transcriptomicsNature Methods named spatially resolved transcriptomics Method of the Year 2020. The field combines imaging and sequencing to map gene expression in tissue context, with methods like Visium and GeoMx. Researchers aim for single-cell resolution and commercial tools.PR NewswireThe global spatial genomics & transcriptomics market size is expected to reach USD 262.7 million by 2025A market research report projects the global spatial genomics and transcriptomics market to reach USD 262.7 million by 2025, growing at an 8.5% CAGR, driven by demand for cancer diagnostics, genetic tool innovations, and rising investments in genomics studies. Key technological trends include FISH dominating revenue share while massively parallel sequencing is expected to grow rapidly, with consumables holding the largest revenue share and software products benefiting from strategic alliances. North America currently leads the market while Asia Pacific is projected to show the fastest growth, with companies like 10x Genomics, Illumina, and NanoString Technologies among key players contributing to market expansion.FinSMEs10x Genomics Acquires Spatial Transcriptomics10x Genomics acquired Spatial Transcriptomics, a Stockholm-based spatial genomics company, for an undisclosed amount. The technology, developed at Science for Life Laboratory, enables 2D RNA sequencing and is used by pharmaceutical companies and universities. 10x Genomics will keep Spatial Transcriptomics in Stockholm and expand its presence in Sweden's scientific community.PR Newswire10x Genomics Acquires Spatial Transcriptomics10x Genomics announced the acquisition of Stockholm-based Spatial Transcriptomics, a pioneer in spatial genomics. The company's technology captures the transcriptome from tissue sections, bridging microscopy and RNA sequencing. 10x will keep Spatial Transcriptomics in Stockholm and expand its presence in Sweden.ForbesBuzzy Startup 10x Genomics Buys Spatial Transcriptomics In Bet On Genetic Tools10x Genomics is acquiring Stockholm-based Spatial Transcriptomics for an undisclosed sum to add a genetic imaging tool to its product line. The company reported $71 million in annual sales last year and has raised $208 million from investors, including a $125 million round that valued it at $925 million.